Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients.

abstract：AIM:In order to administer antipsychotic medication with the most beneficial outcome, the appropriate drug and dose needs to be identified. Though often not considered in pharmacogenetic studies, dosage plays an important role in treatment outcome. This study set out to analyze the association between 109 SNPs and anti...

journal_title：Pharmacogenomics

authors： Hettige NC,de Moraes GH,Kennedy JL,De Luca V

更新日期：2016-02-01 00:00:00

abstract：:High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients...

journal_title：Pharmacogenomics

authors： Aghabozorg Afjeh SS,Shams J,Hamednia S,Boshehri B,Olfat A,Omrani MD

更新日期：2020-09-01 00:00:00

abstract：:A letter in response to: Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics 13(7), 757-762 (2012). ...

journal_title：Pharmacogenomics

authors： Botton MR,Hutz MH,Suarez-Kurtz G

更新日期：2012-11-01 00:00:00

abstract：:Pharmacogenomic analyses will become crucial to predict patients' toxicity to treatment and will also help to predict the tumor response. Processes of drug metabolism, drug efflux, DNA-repair and characteristics of drug targets are critical checkpoints of drug efficacy. These crucial pathways for drug action have been...

journal_title：Pharmacogenomics

authors： Stoehlmacher J,Goekkurt E,Lenz HJ

更新日期：2003-11-01 00:00:00

abstract：:Multiple sclerosis (MS) is a condition of the CNS marked by inflammation and neurodegeneration. Interferon (IFN)-beta was the first, and still is the main, immunomodulatory treatment for MS. Its clinical efficacy is limited, and a proportion of patients, ranging between 20-55%, do not respond to the therapy. Identific...

journal_title：Pharmacogenomics

authors： Vandenbroeck K,Urcelay E,Comabella M

更新日期：2010-08-01 00:00:00

abstract：:miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...

journal_title：Pharmacogenomics

authors： Singh SK

更新日期：2007-08-01 00:00:00

abstract：:Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

journal_title：Pharmacogenomics

authors： Schumacher-Schuh AF,Rieder CR,Hutz MH

更新日期：2014-06-01 00:00:00

abstract：:Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

journal_title：Pharmacogenomics

authors： Vucic EA,Brown CJ,Lam WL

更新日期：2008-02-01 00:00:00

abstract：:Despite their clearly distinct pathophysiologies, HIV and cancer are diseases whose response to chemotherapy treatment varies substantially amongst patients, in particular for those with prior drug exposure. This has been attributed, in part, to elevated expression of the ABCB1 drug transporter in some patients, which...

journal_title：Pharmacogenomics

authors： Reed K,Parissenti AM

更新日期：2011-10-01 00:00:00

abstract：INTRODUCTION:Polymorphic alleles in the human genome have been identified as affecting numerous drug responses. Currently, genotyping of all patients before starting a drug regimen is impractical. Since many polymorphisms occur at varying rates in different racial groups, we investigated whether a patient's race could ...

journal_title：Pharmacogenomics

authors： Yen-Revollo JL,Auman JT,McLeod HL

更新日期：2008-11-01 00:00:00

abstract：:Migraine is considered one of the most disabling neurological disorder with a high socioeconomic burden. Pharmacological management includes many classes of drugs which in the most cases, are administrated in polytherapy. The therapeutic scheme of migraineurs is often affected by comorbidities which need concomitant m...

journal_title：Pharmacogenomics

authors： Borro M,Guglielmetti M,Simmaco M,Martelletti P,Gentile G

更新日期：2019-11-01 00:00:00

abstract：:Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

journal_title：Pharmacogenomics

authors： Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

更新日期：2008-12-01 00:00:00

abstract：:The ultrarapid CYP2D6 metabolizer (UM) phenotype is caused by CYP2D6 gene duplications in some, but not all, UM individuals. CYP2D6 and the adjacent pseudogene CYP2D7 are highly homologous; however, CYP2D7 harbors a premature stop codon, which is absent in carriers of the rare CYP2D7 variant rs530303678. We addressed ...

journal_title：Pharmacogenomics

authors： Jukic MM,Lauschke VM,Saito T,Hiratsuka M,Ingelman-Sundberg M

更新日期：2018-08-01 00:00:00

abstract：:While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...

journal_title：Pharmacogenomics

authors： Narasimhan S,Lohoff FW

更新日期：2012-03-01 00:00:00

abstract：AIMS:To determine the extent of pharmacogenomics instruction at US and Canadian medical schools, characterize perceptions of curricular coverage, identify curricular resources and compare responses with similar studies conducted in US pharmacy schools and British medical schools. MATERIALS & METHODS:A survey was sent ...

journal_title：Pharmacogenomics

authors： Green JS,O'Brien TJ,Chiappinelli VA,Harralson AF

更新日期：2010-09-01 00:00:00

abstract：:Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...

journal_title：Pharmacogenomics

authors： John SE,Antony D,Eaaswarkhanth M,Hebbar P,Alkayal F,Tuomilehto J,Alsmadi O,Thanaraj TA

更新日期：2017-06-01 00:00:00

abstract：AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...

journal_title：Pharmacogenomics

authors： Wang D,Li Q,Favis R,Jadwin A,Chung H,Fu DJ,Savitz A,Gopal S,Cohen N

更新日期：2014-01-01 00:00:00

abstract：:Second-generation antipsychotics can greatly improve symptoms of psychosis-spectrum disorders. Unfortunately, these drugs are associated with weight gain, which increases a patient's risk for developing chronic diseases including Type 2 diabetes, cardiovascular diseases or other obesity-related complications. There ar...

journal_title：Pharmacogenomics

authors： Lee AK,Bishop JR

更新日期：2011-07-01 00:00:00

abstract：:Discovery Partners International (Nasdaq: DPII) is a leader in collaborative drug discovery. DPI's integrated discovery framework encompasses a broad spectrum of capabilities in chemistry, biology, informatics, computational modeling and synthesis automation. DPI's approach to drug discovery places a heavy emphasis on...

journal_title：Pharmacogenomics

authors： Herd C

更新日期：2002-01-01 00:00:00

abstract：:The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

journal_title：Pharmacogenomics

authors： Hawkins GA,Weiss ST,Bleecker ER

更新日期：2008-03-01 00:00:00

abstract：:The investigational drug dichloroacetate (DCA) is a metabolic regulator that has been successfully used to treat acquired and congenital metabolic diseases and, recently, solid tumors. Its clinical use has revealed challenges in selecting appropriate doses. Chronic administration of DCA leads to inhibition of DCA meta...

journal_title：Pharmacogenomics

authors： James MO,Stacpoole PW

更新日期：2016-05-01 00:00:00

abstract：:Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in h...

journal_title：Pharmacogenomics

authors： Manunta P,Citterio L,Lanzani C,Ferrandi M

更新日期：2007-05-01 00:00:00

abstract：:Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant and nonmalignant disorders. Busulfan (Bu) and cyclophosphamide (Cy) are the most commonly used alkylators in high-dose pretransplant conditioning for HSCT; a treatment that is correlated with drug-related toxicity and relapse....

journal_title：Pharmacogenomics

authors： Hassan M,Andersson BS

更新日期：2013-01-01 00:00:00

abstract：AIM:To determine if copy number variants contribute to warfarin dose requirements, we investigated CYP2C9, VKORC1, CYP4F2, GGCX and CALU for deletions and duplications in a multiethnic patient population treated with therapeutic doses of warfarin. PATIENTS & METHODS:DNA samples from 178 patients were subjected to copy...

journal_title：Pharmacogenomics

authors： Scott SA,Patel M,Martis S,Lubitz SA,van der Zee S,Yoo C,Edelmann L,Halperin JL,Desnick RJ

更新日期：2012-02-01 00:00:00

abstract：:The recent introduction of new microarray expression technologies and the further development of established platforms ensure that the researcher is presented with a range of options for performing an experiment. Whilst this has opened up the possibilities for future applications, such as exon-specific arrays, increas...

journal_title：Pharmacogenomics

authors： Elvidge G

更新日期：2006-01-01 00:00:00

abstract：:Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranuloc...

journal_title：Pharmacogenomics

authors： Legge SE,Walters JT

更新日期：2019-03-01 00:00:00

abstract：:The current paradigm of human genetics research is to analyze variation of a single data type (i.e., DNA sequence or RNA levels) to detect genes and pathways that underlie complex traits such as disease state or drug response. While these studies have detected thousands of variations that associate with hundreds of co...

journal_title：Pharmacogenomics

authors： Holzinger ER,Ritchie MD

更新日期：2012-01-01 00:00:00

abstract：:Founded as a spin-off from the University of Vienna in 1999, VBC-GENOMICS Bioscience Research GmbH (LLC) has rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company has focused on the dev...

journal_title：Pharmacogenomics

authors： Schmidt WM

更新日期：2004-06-01 00:00:00

abstract：:Pharmacogenetics has been driven by a candidate gene approach. The disadvantage of this approach is that is limited by our current understanding of the mechanisms by which drugs act. Gene expression could help to elucidate the molecular signatures of antipsychotic treatments searching for dysregulated molecular pathwa...

journal_title：Pharmacogenomics

authors： Mas S,Gassó P,Lafuente A

更新日期：2015-11-01 00:00:00

abstract：AIM:This study aimed to explore the role of miRNAs in rifampin-mediated induction of CYP3A4 in HepaRG cells. MATERIALS & METHODS:Microarray was performed to determine the expression of miRNAs in rifampin-treated HepaRG cells, followed by bioinformatics and luciferase reporter gene assay to analyze miRNAs that directly...

journal_title：Pharmacogenomics

authors： Yan L,Liu J,Zhao Y,Nie Y,Ma X,Kan Q,Zhang L

更新日期：2017-01-01 00:00:00